While mental health has previously been the focus of psychedelics research, the drug class is also emerging in neurological and inflammation-driven diseases.
The biopharma industry of Europe can use AI to leverage its vast stores of health data to address key challenges.
MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close in.
Its use will depend on strategies that integrate close monitoring and multidisciplinary care.
The Carlsbad facility will begin commercial production once regulatory approval is obtained.
The companies will build on their respective strengths and expertise to accelerate progress in AI-enabled biologics research.
